{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"027-113-406-891-351","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"027-113-406-891-351"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11993,"type":"PATENT","title":"University of Connecticut Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":3197,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8558,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:Univ* Connecti*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2880
Search Applicants and Owners separately:Univ* Connecti*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2880
(a) administering to the subject at least one treatment modality, wherein said at least one treatment modality comprises a tyrosine kinase inhibitor; and\n
(b) administering a purified heat shock protein preparation."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the cancer is chronic myelogenous leukemia."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 2 wherein the cancer is in chronic phase."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the cancer is a soft tissue sarcoma."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the cancer is a gastrointestinal stromal tumor expressing the tyrosine kinase receptor c-kit."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the tyrosine kinase inhibitor is a tyrphostin."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the tyrosine kinase inhibitor is selected from the group consisting of imatinib mesylate, herbimycin A, genistein, erbstatin, and lavendustinA."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the tyrosine kinase inhibitor is imatinib mesylate."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the subject has previously been non-responsive to treatment with at least one second treatment modality in the absence of a heat shock protein preparation."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the purified heat shock protein preparation comprises one or more heat shock protein-peptide complexes wherein the heat shock protein is hsp60, hsp70, hsp90, hsp110, gp96, or caireticulin."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the purified heat shock protein preparation comprises hsp70."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the purified heat shock protein preparation is autologous to the subject being treated."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the subject is human."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the treatment modality is administered prior to an initial administration of the heat shock protein preparation."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the treatment modality is administered concurrently with said administering of the heat shock protein preparation."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the treatment modality is administered subsequent to an initial administration of the heat shock protein preparation."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["A method of treating chronic myelogenous leukemia in a subject comprising:\n
(a) administering to the subject at least one treatment modality, wherein said at least one treatment modality comprises imatinib mesylate; and\n
(b) administering a purified heat shock protein preparation."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17 wherein the subject is human."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17 wherein said imatinib mesylate is administered daily."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19 wherein said imatinib mesylate is administered at 400 mg daily."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19 wherein said imatinib mesylate is administered at 600 mg daily."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 19 wherein said imatinib mesylate is administered at 800 mg in two daily doses of 400 mg each."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17 wherein said imatinib mesylate is administered prior to an initial administration to the subject of the heat shock protein preparation."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17 wherein said imatinib mesylate is administered concurrently with said administering of the heat shock protein preparation."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17 wherein said imatinib mesylate is administered subsequent to an initial administration to the subject of the heat shock protein preparation."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["A method of treating chronic myelogenous leukemia in a subject receiving 200 mg to 800 mg of imatinib mesylate daily comprising administering a heat shock protein preparation to said subject, wherein said heat shock protein preparation comprises hsp70-peptide complexes."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 26 wherein said hsp70-peptide complexes are isolated from tumor cells obtained from said subject."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 26 wherein said heat shock protein preparation is administered once a week."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 or 17 further comprising administering a second treatment modality that is not a vaccine."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein said heat shock protein preparation comprises a population of heat shock protein-peptide complexes, and wherein said peptide displays the antigenicity of a tumor-specific antigen or tumor-associated antigen of the type of said cancer in said subject."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein said heat shock protein preparation comprises a population of heat shock protein-peptide complexes obtained from cancerous tissue of the type of said cancer in said subject."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17 wherein said heat shock protein preparation comprises a population of heat shock protein-peptide complexes obtained from chronic myelogenous leukemia tissue in said subject."],"number":32,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein said heat shock protein preparation is administered in an amount ineffective for treatment of said cancer when administered in the absence of said treatment modality."],"number":33,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17 wherein said subject has previously been non-responsive to treatment with said treatment modality in the absence of said heat shock protein preparation."],"number":34,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 or 17 further comprising administering to the subject cyclophosphamide."],"number":35,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 or 17 further comprising administering to the subject a cytokine."],"number":36,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 or 17 further comprising administering to the subject IL-12."],"number":37,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 29 wherein the subject is human."],"number":38,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 29 wherein said heat shock protein preparation comprises one or more heat shock protein-peptide complexes wherein the heat shock protein is hsp60, hsp70, hsp90, hsp110, gp96, grp170 or calreticulin."],"number":39,"annotation":false,"title":false,"claim":true},{"lines":["A method for improving the treatment outcome in a subject in need of treatment for cancer comprising the steps of:\n
(a) administering to said subject a sub-optimal amount of a purified heat shock protein preparation comprising a population of heat shock protein-peptide complexes that (i) display the antigenicity of a tumor-specific antigen or tumor-associated antigen of the type of said cancer or (ii) are isolated from cancerous tissue of said subject; and\n
(b) subsequent to step (a), administering to said subject at least one treatment modality in an amount effective for treatment of said cancer; wherein said treatment modality comprises a tyrosine kinase inhibitor; wherein in the absence of step (b), said sub-optimal amount is ineffective for treatment of said cancer; and wherein in the absence of step (a), said at least one treatment modality is ineffective for treatment of said cancer."],"number":40,"annotation":false,"title":false,"claim":true},{"lines":["A method of treating cancer in a subject comprising:\n
(a) administering to the subject a purified heat shock protein preparation comprising a population of noncovalent heat shock protein-peptide complexes obtained from cancerous tissue of the subject; and\n
(b) subsequent to step (a), administering to the subject at least one treatment modality, wherein said treatment modality comprises a tyrosine kinase inhibitor."],"number":41,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 41 in which step (b) further comprises administering a cytokine to the subject."],"number":42,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 42 wherein the at least one treatment modality and the cytokine are administered on the same day, the heat shock protein preparation is administered on a different day, and the heat shock protein preparation and the at least one treatment modality are administered within a time frame wherein both are still active."],"number":43,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 43 wherein the at least one treatment modality is imatinib mesylate and the cytokine is IL-12."],"number":44,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 41 wherein the subject is human."],"number":45,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 41 wherein the heat shock protein preparation is administered one or more days prior to the at least one treatment modality, and the heat shock protein preparation and the at least one treatment modality are administered within a time frame wherein both are still active."],"number":46,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 41 wherein the heat shock protein preparation is administered at least two weeks prior to said at least one treatment modality, and the heat shock protein preparation and the at least one treatment modality are administered within a time frame wherein both are still active."],"number":47,"annotation":false,"title":false,"claim":true},{"lines":["A method for treating cancer in a subject comprising\n
(a) administering to a subject having cancer a purified alpha-2-macroglobulin preparation; and\n
(b) subsequent to step (a), administering to the subject a treatment modality, wherein the treatment modality comprises a tyrosine kinase inhibitor."],"number":48,"annotation":false,"title":false,"claim":true},{"lines":["A method of treating cancer in a subject comprising\n
(a) administering to the subject a purified alpha-2-macroglobulin preparation comprising a population of noncovalent alpha-2-macroglobulin-peptide complexes obtained from cancerous tissue of the subject; and\n
(b) subsequent to step (a), administering to the subject at least one treatment modality, wherein the treatment modality comprises a tyrosine kinase inhibitor."],"number":49,"annotation":false,"title":false,"claim":true},{"lines":["A method for improving the treatment outcome in a subject in need of treatment for cancer comprising the steps of:\n
(a) administering to said subject a sub-optimal amount of a purified alpha-2-macroglobulin preparation comprising a population of alpha-2-macroglobulin-peptide complexes that (i) display the antigenicity of a tumor-specific antigen or tumor-associated antigen of said type of cancer or (ii) are isolated from cancerous tissue of said subject; and\n
(b) subsequent to step (a), administering to said subject at least one treatment modality in an amount effective for treatment of said cancer; wherein said at least one treatment modality comprises a tyrosine kinase inhibitor; wherein in the absence of step (b), said sub-optimal amount is ineffective for treatment of said cancer and wherein in the absence of step (a), said cancer does not respond to said treatment modalities."],"number":50,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17 wherein the purified heat shock protein preparation comprises one or more heat shock protein-peptide complexes wherein the heat shock protein is hsp60, hsp70, hsp90, hsp110, gp96, or calreticulin."],"number":51,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17 wherein the purified heat shock protein preparation comprises hsp70."],"number":52,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17 wherein the purified heat shock protein is autologous to the subject being treated."],"number":53,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17 wherein said heat shock protein preparation comprises a population of heat shock protein-peptide complexes, and wherein said peptide displays the antigenicity of a chronic myelogenous leukemia tumor-specific antigen or tumor-associated antigen."],"number":54,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17 wherein said heat shock protein preparation is administered in an amount ineffective for treatment of chronic myelogenous leukemia when administered in the absence of said treatment modality."],"number":55,"annotation":false,"title":false,"claim":true},{"lines":["A method for improving the treatment outcome in a subject in need of treatment for cancer comprising the steps of:\n
(a) administering to said subject a sub-optimal amount of at least one treatment modality; wherein said treatment modality comprises a tyrosine kinase inhibitor; and\n
(b) subsequent to step (a), administering to said subject a purified heat shock protein preparation comprising a population of heat shock protein-peptide complexes that (i) display the antigenicity of a tumor-specific antigen or tumor-associated antigen of the type of said cancer or (ii) are isolated from cancerous tissue of said subject, in an amount effective for treatment of said cancer; wherein in the absence of step (b), said sub-optimal amount is ineffective for treatment of said cancer; and wherein in the absence of step (a), said heat shock protein preparation modality is ineffective for treatment of said cancer."],"number":56,"annotation":false,"title":false,"claim":true},{"lines":["A method of treating cancer in a subject comprising:\n
(a) administering to the subject at least one treatment modality, wherein said treatment modality comprises a tyrosine kinase inhibitor; and\n
(b) subsequent to step (a), administering to the subject a purified heat shock protein preparation comprising a population of noncovalent heat shock protein-peptide complexes obtained from cancerous tissue of the subject."],"number":57,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 40, 50, or 56 wherein the cancer is chronic myelogenous leukemia."],"number":58,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 58 wherein the cancer is in chronic phase."],"number":59,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 40, 50, or 56 wherein the tyrosine kinase inhibitor is selected from the group consisting of imatinib mesylate, herbimycin A, genistein, erbstatin, and lavendustinA."],"number":60,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 40, 50, or 56 wherein the tyrosine kinase inhibitor is imatinib mesylate."],"number":61,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 61 wherein the imatinib mesylate is administered daily."],"number":62,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 40, 50, or 56 wherein the subject is human."],"number":63,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 40 or 56 wherein the purified heat shock protein preparation comprises one or more heat shock protein-peptide complexes wherein the heat shock protein is hsp60, hsp70, hsp90, hsp110, gp96, or calreticulin."],"number":64,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 40 or 56 wherein the purified heat shock protein preparation comprises one or more heat shock protein-peptide complexes wherein the heat shock protein is hsp70."],"number":65,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 65 wherein the one or more heat shock protein-peptide complexes wherein the heat shock protein is hsp70 are isolated from tumor cells obtained from said subject."],"number":66,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 40 or 56 wherein the heat shock protein complexes are autologous to the subject being treated."],"number":67,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 or 17 wherein the heat shock protein preparation is administered once a week."],"number":68,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 or 17 wherein the purified heat shock protein preparation comprises gp96."],"number":69,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 or 17 wherein the purified heat shock protein preparation comprises hsp70-peptide complexes."],"number":70,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 or 17 wherein the purified heat shock protein preparation comprises gp96-peptide complexes."],"number":71,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 or 17 wherein the purified heat shock protein preparation comprises autologous heat shock protein-peptide complexes."],"number":72,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}